Evidence map›Paper›PMID 35351042›Full record

ArticleBMC cancer2022

LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis.

Xiaozhou Zhang, Xiaojian Zhang, Qian Jia, Hongqiang Li, Runsheng Ma, Guang Yang, Fengyan Yin, Nannan Jiang, Detao Yin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaozhou ZhangDepartment of thyroid surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan Province, China.
Xiaojian ZhangDepartment of thyroid surgery, Taian City Central Hospital, No. 29 Longtan Road, Tai'an, 271000, Shandong Province, China.
Qian JiaPharmacy Department, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai'an, 271000, Shandong Province, China.
Hongqiang LiDepartment of thyroid surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan Province, China.
Runsheng MaDepartment of thyroid surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan Province, China.
Guang YangDepartment of thyroid surgery, Taian City Central Hospital, No. 29 Longtan Road, Tai'an, 271000, Shandong Province, China.
Fengyan YinDepartment of thyroid surgery, Taian City Central Hospital, No. 29 Longtan Road, Tai'an, 271000, Shandong Province, China.
Nannan JiangDepartment of thyroid surgery, Taian City Central Hospital, No. 29 Longtan Road, Tai'an, 271000, Shandong Province, China.
Detao YinDepartment of thyroid surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan Province, China. detaoyin@zzu.edu.cn.
First Affiliated Hospital of Zhengzhou University · CNTaian City Central Hospital · CNAffiliated Hospital of Taishan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence and mortality of thyroid cancer (TC) has been steadily rising in the past decades. It is imperative to have a better understanding of the molecular mechanisms underlying TC development and identify novel therapeutic targets. This study characterized the role of lncRNA CALML3-AS1 (CALML3-AS1) in the development of papillary thyroid cancer (PTC).

methodRelated mRNAs expression were validated in the tumor and adjacent normal tissues from 52 PTC patients and PTC cell lines by qRT-PCR. Expression of RBM38 was detected by Western blot. We have also conducted CCK-8 and colony formation assays were used to detect the effect of CALML3-AS1 on cell proliferation, Transwell assay was utilized to evaluate cell migration and invasion, apoptosis detected by flow cytometry assay, RNA pull-down and luciferase assays were performed to validate gene predictions.

resultsThe results indicated that the expression of both CALML3A-S1 and RBM38 were significantly downregulated in PTC tissues (p < 0.01), while the expression of miR-20a-5p was increased in PTC (p < 0.01). Functionally, CALML3-AS1 overexpression inhibited PTC cell proliferation in vitro and in vivo. Mechanistically, CALML 3-AS1 sponged miR-20a-5p, which in turn leads to the suppression of RBM38 expression and PTC progression.

conclusionsCALML3-AS1 functions as a ceRNA for miR-20a-5p in the regulation of the expression of RBM38 in PTC. Higher level of CALML3-AS1 serves as a good prognostic indicator of survival in PTC patients. Targeting CALML3-AS1/ miR-20a-5p/RBM38 axis may represent a novel therapeutic strategy in the treatment of PTC.

Indexed as

MicroRNAsRNA, Long NoncodingThyroid NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticHumansRNA-Binding ProteinsThyroid Cancer, PapillaryMicroRNAsMIRN20a microRNA, humanRBM38 protein, humanRNA-Binding ProteinsRNA, Long NoncodinglncRNAlncRNA CALML3-AS1miR-20a-5pPapillary thyroid cancerRBM38

Identifiers

PMID35351042
PMCPMC8966157
OpenAlexW4220945200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.